Novelix Pharmaceuticals Ltd (NOVELIX)

BSE · Healthcare · Healthcare Services · Healthcare Research, Analytics & Technology

₹68.67

As of 30 Oct 2026 close.

Facts from reported results and exchange filings. Not investment advice.

Share price

Prices load here as you scroll to them.

Last close ₹68.67 on 30 Oct 2026. The share price traded between ₹49.01 and ₹92.00 (intraday) over the last 12 months.

The closes as a table

DateClose

Key figures

1-year range (intraday)

Last close ₹68.67

Low ₹49.01High ₹92.00

Market cap₹196 crorelast close × shares
Net profit−₹2.54 crlast 12 months
Dividend yieldnonelast 12 months

Return on equity, margins and debt to equity aren't shown: the newest year in the table ended on 31 Mar 2022, more than 15 months before this price, and a newer annual report's figures aren't on the page yet.

P/E isn't shown: the company made a loss over the last 12 months, and a loss has no P/E.

Price trend

Revenue and profit

RevenueNet profit₹ crore
-5051015
YearMar 2018Mar 2019Mar 2020Mar 2021Mar 2022
Revenue10.5110.7310.859.598.91
Net profit-0.35-0.15-0.26-3.76-2.03
EBITDA margin0.4%1.0%0.9%-36.2%-24.6%
Borrowings0.980.930.770.000.16

₹ crore. Over three years, compounded: revenue fell 6.0% a year.

Recent filings

Questions about Novelix Pharmaceuticals Ltd

What is Novelix Pharmaceuticals Ltd's market value?

Novelix Pharmaceuticals Ltd's market value is ₹196 crore as of 30 Oct 2026 close: the last close times the shares in issue.

Go further with NOVELIX

Free to start: test a trading idea on NOVELIX's real prices after costs, or open the full deep dive with ten years of numbers, red flags and management's record.

Same industry

The largest companies in the same industry (Healthcare Research, Analytics & Technology), by market value.

Browse companies

The companies before and after this one, A to Z, and the lists it is in.

How these figures are worked out

The net profit for the last 12 months is the four latest reported quarters, so it can differ from the newest year's in the table below.